Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Capital Expenditures (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Capital Expenditures for 14 consecutive years, with $50000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 58.68% to $50000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $211000.0 through Dec 2025, down 90.29% year-over-year, with the annual reading at $211000.0 for FY2025, 90.29% down from the prior year.
  • Capital Expenditures hit $50000.0 in Q4 2025 for Corcept Therapeutics, down from $57000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q3 2024 to a low of $12000.0 in Q1 2022.
  • Historically, Capital Expenditures has averaged $212750.0 across 5 years, with a median of $103000.0 in 2023.
  • Biggest five-year swings in Capital Expenditures: crashed 90.48% in 2022 and later surged 4318.92% in 2024.
  • Year by year, Capital Expenditures stood at $65000.0 in 2021, then crashed by 52.31% to $31000.0 in 2022, then rose by 19.35% to $37000.0 in 2023, then skyrocketed by 227.03% to $121000.0 in 2024, then plummeted by 58.68% to $50000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CORT at $50000.0 in Q4 2025, $57000.0 in Q2 2025, and $104000.0 in Q1 2025.